Eli Lilly (LLY) stock vs the S&P 500 and pharmaceutical stocks
As of 2 October 2026, Eli Lilly (LLY) is trailing both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.
Where Eli Lilly stands now
As of 2 October 2026, Eli Lilly is a long-run winner in a weak patch: ahead of the S&P 500 over the longer run, but behind over the past one and three months.
Inside its group, LLY is catching up: ahead of pharmaceutical stocks (PPH) over the past month, still behind over three months. As a group, pharmaceutical stocks are losing ground to the S&P 500 right now. The group is in transition, so the stock's place inside it matters more than usual.
Eli Lilly is 18.8% of PPH, a weight large enough to drive the fund. It sits in 3 of the sector and theme funds Zensei tracks. The thing to watch is the past month: a turn against the market usually shows there first.
LLY vs the S&P 500: returns
Eli Lilly and the S&P 500 (SPY) side by side, over each window Zensei tracks.
Prices as of · computed from daily adjusted closes · how we measure
LLY against pharmaceutical stocks, in depth
See the size of the gap between Eli Lilly and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.
See the full analysisWhich ETFs hold Eli Lilly?
3 funds that Zensei tracks hold LLY, by weight. The fund with the largest weight is its sector on this page.
Eli Lilly competitors
The largest other holdings of VanEck Pharmaceutical ETF (PPH), with their return over the past month.
Eli Lilly stock: common questions
Is Eli Lilly stock beating the S&P 500?
As of 2 October 2026, Eli Lilly (LLY) is down 1.5% over the past month. The S&P 500 is up 1.3% over the same month. Over three months, the stock is down 5.7% and the S&P 500 is up 3.6%.
Which ETFs hold Eli Lilly?
As of 2 October 2026, 3 funds that Zensei tracks hold LLY. Its largest weight is in VanEck Pharmaceutical ETF (PPH), at 18.8%. It is also in Health Care Select Sector SPDR (XLV, 15.1%), SPDR S&P 1500 Momentum Tilt ETF (MMTM, 2.1%).
Who are Eli Lilly's competitors?
As of 2 October 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) are Merck & Co Inc (MRK), Novartis AG (NVS), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb Co (BMY). These are the stocks Eli Lilly sits next to among pharmaceutical stocks.
Is Eli Lilly doing better than other pharmaceutical stocks?
As of 2 October 2026, Eli Lilly (LLY) is behind pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.
Track Eli Lilly against pharmaceutical stocks and the market
Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.